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Background: The emergence of the everolimus-eluting stent has generated large amounts of clinical trial data comparing this option to paclitaxel-
eluting stents. This study aimed to show the noninferiority of the TAXUS Liberte (TL) stent to the XIENCE V (XV) stent at 1-year follow-up.
Methods: The study included a US all-comers population treated with either TL or XV stents, at 10 sites. Patients receiving TL (n=595) and XV 
(n=600) were compared at 1-year post-implantation. The primary endpoint is major adverse cardiac events (MACE), a composite of all-cause death, 
Q-wave myocardial infarction, and target vessel revascularization. Secondary endpoints include stent thrombosis, target lesion revascularization and 
cardiac death. There is also a subanalysis comparing diabetics and nondiabetics.
Results: Baseline demographics were similar between groups except the TL group was older while the XV group had more hypertension and family 
history of CAD. In-hospital outcomes were similar between groups. At 1 year, MACE was significantly higher in the TL group (11.6% vs. 8.0%, p=0.037). 
After adjusting for baseline differences there was a 66% decrease in MACE at 1 year for patients receiving XV vs TL (1.66 [1.51-2.11], p=0.008). 
(Figure) In the diabetic group this finding was not consistent (9.0% vs 13.6% XV and TL, respectively, p=0.143).
Conclusions: In regards to the primary endpoints, the XV stent was found to be superior to TL, mainly driven by a TLR rate in the TL group with no 
difference in death, MI or ST. 
